Based on the AbbVie Inc stock forecast from 13 analysts, the average analyst target price for AbbVie Inc is USD 203.73 over the next 12 months. AbbVie Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AbbVie Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, AbbVie Inc’s stock price was USD 203.55. AbbVie Inc’s stock price has changed by +8.36% over the past week, +4.14% over the past month and +43.93% over the last year.
No recent analyst target price found for AbbVie Inc
No recent average analyst rating found for AbbVie Inc
Company Overview AbbVie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 Read Less
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Cro...Read More
Frequently Asked Questions About AbbVie Inc (ABBV) Stock
Based on ratings from 13 analysts AbbVie Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 19 buy, sell and 3 hold ratings.
ABBV stock's dividend yield is 3.22%.
Our analysis grades ABBV stock's dividend yield at F. This means that ABBV stock's dividend yield is above 57% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this ABBV may be a average dividend stock for its sector.
Based on targets from 13 analysts, the average taret price for ABBV is USD 203.73 over the next 12 months. The maximum analyst target price is USD 231 while the minimum anlayst target price is USD 172.
ABBV stock's Price/Earning ratio is 70.92.
Our analysis grades ABBV stock's Price / Earning ratio at F. This means that ABBV stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this ABBV may be a overvalued for its sector.
The last closing price of ABBV's stock was USD 203.55.
The most recent market capitalization for ABBV is USD 359.54B.
Based on targets from 13 analysts, the average taret price for ABBV is projected at USD 203.73 over the next 12 months.
This means that ABBV's stock price may go up by +0.09% over the next 12 months.
We can't find any ETFs which contains AbbVie Inc's stock.
As per our most recent records AbbVie Inc has 50,000 Employees.
AbbVie Inc's registered address is 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400.
You can get more information about it from AbbVie Inc's website at https://www.abbvie.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About AbbVie Inc (ABBV) Stock
Based on ratings from 13 analysts AbbVie Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 19 buy, sell and 3 hold ratings.
ABBV stock's dividend yield is 3.22%.
Our analysis grades ABBV stock's dividend yield at F. This means that ABBV stock's dividend yield is above 57% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this ABBV may be a average dividend stock for its sector.
Based on targets from 13 analysts, the average taret price for ABBV is USD 203.73 over the next 12 months. The maximum analyst target price is USD 231 while the minimum anlayst target price is USD 172.
ABBV stock's Price/Earning ratio is 70.92.
Our analysis grades ABBV stock's Price / Earning ratio at F. This means that ABBV stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this ABBV may be a overvalued for its sector.
The last closing price of ABBV's stock was USD 203.55.
The most recent market capitalization for ABBV is USD 359.54B.
Based on targets from 13 analysts, the average taret price for ABBV is projected at USD 203.73 over the next 12 months.
This means that ABBV's stock price may go up by +0.09% over the next 12 months.
We can't find any ETFs which contains AbbVie Inc's stock.
As per our most recent records AbbVie Inc has 50,000 Employees.
AbbVie Inc's registered address is 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400.
You can get more information about it from AbbVie Inc's website at https://www.abbvie.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABBV !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
